Pages that link to "Q24684224"
Jump to navigation
Jump to search
The following pages link to CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2 (Q24684224):
Displaying 25 items.
- ATP-dependent chromatin remodeling complexes as novel targets for cancer therapy (Q26849467) (← links)
- Nrf2 expression is regulated by epigenetic mechanisms in prostate cancer of TRAMP mice (Q33523039) (← links)
- Multi-platform whole-genome microarray analyses refine the epigenetic signature of breast cancer metastasis with gene expression and copy number (Q33525058) (← links)
- Decreased expression of EFS is correlated with the advanced prostate cancer. (Q34442484) (← links)
- Downregulation of 14-3-3σ correlates with multistage carcinogenesis and poor prognosis of esophageal squamous cell carcinoma (Q35152011) (← links)
- MicroRNA-mediated drug resistance in breast cancer (Q35165126) (← links)
- Methyl-binding domain protein 2-dependent proliferation and survival of breast cancer cells. (Q35169101) (← links)
- Overexpression of MBD2 in glioblastoma maintains epigenetic silencing and inhibits the antiangiogenic function of the tumor suppressor gene BAI1 (Q35190706) (← links)
- Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer (Q35699282) (← links)
- Comparative analysis of 14-3-3 isoform expression and epigenetic alterations in colorectal cancer (Q35827925) (← links)
- Epigenetic inactivation of the tissue inhibitor of metalloproteinase-2 (TIMP-2) gene in human prostate tumors (Q36157135) (← links)
- Targeting the unique methylation pattern of androgen receptor (AR) promoter in prostate stem/progenitor cells with 5-aza-2'-deoxycytidine (5-AZA) leads to suppressed prostate tumorigenesis (Q36407872) (← links)
- Study of promoter methylation pattern of 14-3-3 sigma gene in normal and cancerous tissue of breast: A potential biomarker for detection of breast cancer in patients (Q36529431) (← links)
- Small interfering RNA directed reversal of urokinase plasminogen activator demethylation inhibits prostate tumor growth and metastasis (Q36666169) (← links)
- MeCP2 suppresses LIN28A expression via binding to its methylated-CpG islands in pancreatic cancer cells (Q37046644) (← links)
- Stroma-epithelium crosstalk in prostate cancer (Q37355741) (← links)
- Genomic approaches to outcome prediction in prostate cancer (Q37526789) (← links)
- The Roles of the Methyl-CpG Binding Proteins in Cancer (Q37937460) (← links)
- Methyl-CpG-binding domain proteins: readers of the epigenome (Q38451083) (← links)
- Methyl-CpG-binding protein MBD2 plays a key role in maintenance and spread of DNA methylation at CpG islands and shores in cancer. (Q38748279) (← links)
- Sulforaphane enhances Nrf2 expression in prostate cancer TRAMP C1 cells through epigenetic regulation. (Q39193275) (← links)
- Epigenetic alterations in TRAMP mice: epigenome DNA methylation profiling using MeDIP-seq (Q49985254) (← links)
- Reduced MBD2 expression enhances airway inflammation in bronchial epithelium in COPD. (Q54256495) (← links)
- Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials (Q92221539) (← links)
- DNA Methylation Readers and Cancer: Mechanistic and Therapeutic Applications (Q93065274) (← links)